# Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

> **NCT07179380** · PHASE3 · RECRUITING · sponsor: **Insmed Incorporated** · enrollment: 344 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07179380
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-07
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179380, "Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07179380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*